Analyst Reco. Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Real-time Estimate Cboe BZX Other stock markets 12:16:46 2024-06-10 pm EDT			5-day change	1st Jan Change
12.64 ^USD	-1.06%		-3.11%	-12.53%

May. 30	Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million	MT
May. 20	BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	May. 07	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing	May. 06	MT
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing	May. 06	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	Apr. 24	MT
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	Apr. 22	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	Feb. 28	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	Feb. 27	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	Feb. 27	MT
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	Nov. 07	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	23-10-31	MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating	23-08-08	MT
HC Wainwright Raises Price Target on Day One Biopharmaceuticals to $50 From $45, Keeps Buy Rating	23-06-05	MT
Needham Cuts Price Target on Day One Biopharmaceuticals to $40 From $44, Maintains Buy Rating	23-05-08	MT
BofA Securities Downgrades Day One Biopharmaceuticals to Underperform From Buy, Adjusts Price Target to $9 From $34	23-04-25	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $44 From $48, Keeps Buy Rating	23-04-05	MT
Capital One Starts Day One Biopharmaceuticals at Overweight With $40 Price Target	23-02-08	MT
Oppenheimer Initiates Coverage on Day One Biopharmaceuticals With Perform Rating	23-02-03	MT
Piper Sandler Adjusts Day One Biopharmaceuticals' Price Target to $45 From $40, Keeps Overweight Rating	23-01-09	MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $45 From $35, Maintains Buy Rating	23-01-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Analyst Reco.

Filters